Boston Scientific price target raised to $70 from $60 at Barclays

Barclays raised the firm’s price target on Boston Scientific to $70 from $60 and keeps an Overweight rating on the shares after its Q4 results and guidance. Investors expected 2024 growth outlook to be toward the lower end of the company’s long-term growth plan of 8%-10%, and that is exactly what the company delivered, the analyst tells investors in a research note. Farapulse approval coming a month or two early was a positive from the quarter, though this was partially offset by the modest push out of Boston Scientific’s U.S. TAVR launch, the firm added.